Search information pages
About Journal of Hematology & Oncology
This page includes information about the aims and scope of Journal of Hematology & Oncology, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Aims & scope
Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology.
Hematology and oncology are closely intertwined and rapidly evolving fields. More physician scientists performing laboratory-based research are rapidly bringing research in hematology and oncology from bench to bedside. Journal of Hematology & Oncology aims to meet the demand for a journal dedicated to publishing discovery from both of these fields.
Journal of Hematology & Oncology aims to serve as an international platform for sharing laboratory and clinical findings in an open access format among laboratory scientists, physician scientists, hematologists and oncologists. A rapid turnaround time from submission to publication means that knowledge and new successes can be shared in real time.
All articles published by Journal of Hematology & Oncology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
Authors of articles published in Journal of Hematology & Oncology are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.
For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Journal of Hematology & Oncology therefore levies an article-processing charge of £1290/$2110/€1550 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors.
All articles published in Journal of Hematology & Oncology are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Journal of Hematology & Oncology include:
- Cases Database
- Current contents
- Google Scholar
- PubMed Central
- Science Citation Index Expanded
The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands). All case reports published in this journal will also be indexed in Cases Database.
Journal of Hematology & Oncology is tracked by Thomson Reuters (ISI) and has an Impact Factor of 4.46.
Publication and peer review process
Criteria for publication
Journal of Hematology & Oncology considers the following types of articles:
Research: reports of data from original research.
Reviews:comprehensive, authoritative, descriptions of any subject within the journal's scope. Reviews can cover any topical themes such as basic science and clinical reviews, ethics, pro/con debates, equipment reviews and thematic series to highlight specific topics in the field.
Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. These can also be used to present unexpected or unusual images of a disease. All case report articles should indicate that informed consent to publish the information was granted from the patients or their guardians.
Letters to the Editor brief laboratory and clinical studies should be submitted in this format for rapid communication. Reports of individual cases which may impact and /or enhance clinical practice or diagnostic understanding can also be submitted in this format. These can also take other forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of the original publication, or an article that may not cover 'standard research' but that may be relevant to readers.
Rapid communications: preliminary results of significant interest that are particularly topical and relevant, and for which fast publication is essential.
Journal of Hematology & Oncology has a 'closed' peer review policy. All submitted manuscripts will be screened before being sent to two peer reviewers. The Editor-in-Chief and Associate Editors are routinely involved in decision-making, but final decisions lie with the Editor-in-Chief. The journal aims to reach a first decision within six weeks. If an author has queries or is unhappy with a decision, there will be a discussion involving the Editor-in-Chief and at least one of the Associate Editors who were not involved in the initial reviewing.
Edited by Delong Liu, Journal of Hematology & Oncology is supported by an expert Editorial Board.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Journal of Hematology & Oncology, a personalized section of the site.
High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.
Journal of Hematology & Oncology will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.
All manuscripts submitted to Journal of Hematology & Oncology should adhere to BioMed Central's editorial policies.
Citing articles in Journal of Hematology & Oncology
Articles in Journal of Hematology & Oncology should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. J Hematol Oncol [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. J Hematol Oncol 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in Journal of Hematology & Oncology?
Journal of Hematology & Oncology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
Journal of Hematology & Oncology offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browsable web form, and as a formatted PDF; the article will then be available through Journal of Hematology & Oncology, BioMed Central and PubMed Central and will also be included in PubMed.
Online publication in Journal of Hematology & Oncology gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Journal of Hematology & Oncology are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Journal of Hematology & Oncology's pages and on the BioMed Central homepage.
In addition, articles published in Journal of Hematology & Oncology may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal of Hematology & Oncology. A list of articles recently press-released by journals published by BioMed Central is available here.
Authors of articles published in Journal of Hematology & Oncology retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.